Patents by Inventor Enda Kenny

Enda Kenny has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210283226
    Abstract: Stable liquid formulations of GLP-1 and GLP-1 analogues and method of using such formulations in the treatment of disorders or conditions are provided.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 16, 2021
    Applicant: Rose Pharma LLC
    Inventors: Andrea HAWE, Eva KEILHAUER, Olimpia POPKO, Enda KENNY, Richard WARBURG
  • Patent number: 11058748
    Abstract: Stable liquid formulations of GLP-1 and GLP-1 analogues and method of using such formulations in the treatment of disorders or conditions are provided.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: July 13, 2021
    Assignee: Rose Pharma LLC
    Inventors: Andrea Hawe, Eva Keilhauer, Olimpia Popko, Enda Kenny, Richard Warburg
  • Patent number: 11045578
    Abstract: The invention provides a three dimensional (3D), porous, biodegradable and biocompatible tissue engineering scaffold, wherein at least 25% w/w of the scaffold is particulate egg shell membrane (ESM) distributed substantially uniformly therein and the scaffold is essentially dry. Methods for preparing the same by freeze-drying and cryogelation and the use thereof in methods of tissue engineering and to promote the healing of wounds are also provided.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: June 29, 2021
    Assignee: BIOVOTEC AS
    Inventors: Enda Kenny, Ralf Schmidt, Henri-Pierre Suso, Matthias Schnabelrauch, Annika Wartenberg
  • Publication number: 20210169987
    Abstract: Stable liquid formulations of GLP-1 and GLP-1 analogues and method of using such formulations in the treatment of disorders or conditions are provided.
    Type: Application
    Filed: December 2, 2020
    Publication date: June 10, 2021
    Applicant: Rose Pharma LLC
    Inventors: Andrea HAWE, Eva KEILHAUER, Olimpia POPKO, Enda KENNY, Richard WARBURG
  • Patent number: 10932952
    Abstract: The invention provides a dry biocompatible film comprising at least one film forming material and particulate egg shell membrane (ESM), wherein said particulate ESM is distributed substantially uniformly in and/or on the film and wherein said film, or portion thereof, disintegrates upon contact with a wound or an exudate thereof. The invention further provides methods for preparing the films of the invention and the uses thereof in methods to promote the healing of wounds.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: March 2, 2021
    Assignee: BIOVOTEC AS
    Inventors: Enda Kenny, Ralf Schmidt, Henri-Pierre Suso, Paul Barham
  • Publication number: 20200030492
    Abstract: The invention provides a three dimensional (3D), porous, biodegradable and biocompatible tissue engineering scaffold, wherein at least 25% w/w of the scaffold is particulate egg shell membrane (ESM) distributed substantially uniformly therein and the scaffold is essentially dry. Methods for preparing the same by freeze-drying and cryogelation and the use thereof in methods of tissue engineering and to promote the healing of wounds are also provided.
    Type: Application
    Filed: June 24, 2016
    Publication date: January 30, 2020
    Inventors: ENDA KENNY, RALF SCHMIDT, HENRI-PIERRE SUSO
  • Publication number: 20180325740
    Abstract: The invention provides a dry biocompatible film comprising at least one film forming material and particulate egg shell membrane (ESM), wherein said particulate ESM is distributed substantially uniformly in and/or on the film and wherein said film, or portion thereof, disintegrates upon contact with a wound or an exudate thereof. The invention further provides methods for preparing the films of the invention and the uses thereof in methods to promote the healing of wounds.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 15, 2018
    Inventors: Enda KENNY, Ralf SCHMIDT, Henri-Pierre SUSO, Paul BARHAM
  • Publication number: 20170319629
    Abstract: The invention provides a particle consisting essentially of micronized ESM and having a mean particle diameter of less than 100 ?m for use in promoting the healing of a chronic wound at risk of, or in which there is, (i) an inappropriate level of matrix-metalloproteinase (MMP) activity against extracellular matrix (ECM) proteins and/or peptide growth or differentiation factors, and/or (ii) an excessive inflammatory response. The invention further provides pharmaceutical compositions, wound dressings and implantable medical devices comprising the micronized ESM-containing particles for use in said treatments. The invention still further provides methods for manufacturing the micronized ESM-containing particles and the compositions, dressings and implantable medical devices comprising the same.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 9, 2017
    Inventors: RALF SCHMIDT, HENRI-PIERRE SUSO, ENDA KENNY
  • Patent number: 8642548
    Abstract: A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.
    Type: Grant
    Filed: August 5, 2010
    Date of Patent: February 4, 2014
    Assignee: Mannkind Corporation
    Inventors: Peter Richardson, Enda Kenny, Per Hellstrom, Marshall L. Grant, Grayson W. Stowell, Scott Daniels, Anthony Smithson, Stephanie Greene
  • Publication number: 20120252728
    Abstract: A method of treating functional dyspepsia and/or irritable bowel syndrome in mammals in need of treatment is disclosed herein. The method comprises administering to the mammal a formulation by inhalation, wherein the formulation avoids first pass metabolism of the active ingredient. The method comprises administering a formulation by pulmonary inhalation comprising a diketopiperazine and a glucagon-like peptide (GLP-1), analog, ROSE-010.
    Type: Application
    Filed: August 5, 2010
    Publication date: October 4, 2012
    Inventors: Peter Richardson, Enda Kenny, Per Hellstrom, Marshall L. Grant, Grayson W. Stowell, Scott Daniels, Anthony Smithson, Stephanie Greene